Company / Gross Margin
PLUS THERAPEUTICS, INC. Gross Margin History
FY2011-FY2017 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Gross Margin
41.7%
FY2017
5-year range
34.2% / 41.7%
FY2013-FY2017
Trend
+22.1%
vs FY2016
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Gross Margin returned to growth in FY2017 after 2 years of decline, reaching 41.7%.
Based on SEC 10-K filings.
41.7% in FY2017 with a 5-year CAGR of -11.0%.
Declined from 52.0% to 41.7% over the past 2 years.
Gross Margin over time
Growth rates
- 3-Year Change
- -12.4pp
- 5-Year Change
- -11.0pp
- 10-Year Change
- -
Key checks
Key Insights
- In FY2017, gross margin increased 22.1% year-over-year.
- Peak gross margin was recorded in FY2014.
- Lowest gross margin in the period was in FY2016.
Company context
Key Data Points
- Altman Z-Score -2.46 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Gross MarginValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | - | - |
| FY2024 | - | - |
| FY2018 | - | - |
| FY2017 | 41.7% | +22.1% |
| FY2016 | 34.2% | -34.3% |
| FY2015 | 52.0% | -3.9% |
| FY2014 | 54.1% | +4.1% |
| FY2013 | 51.9% | -1.3% |
| FY2012 | 52.6% | +25.8% |
| FY2011 | 41.9% | - |
As of FY2017 · SEC 10-K · Updated Jun 28, 2026